Demographic characteristics, leukemia genetics, and therapeutic interventions of patients with low Vitamin C
| Patient no. . | Sex . | Age, y . | AML genetics∗ . | Recent or current chemotherapy treatment . | Treatment line . | Platelet count . | Vc level (μmol/L) . | Malnutrition present (yes/no)† . | Parental nutrition . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Subtype . | Pathologic variants present . | Karyotype . | |||||||||
| 1 | F | 57 | AML-MRC | BRAF, NF1, NPM1, DNMT3A‡ | 46,XX,-18,+r[5]/46.XX[15] | Liposomal daunorubicin-cytarabine | Induction | 20 | 7 | Yes | No |
| 2 | M | 73 | M5 | DNMT3A, FLT3, NPM1, BRCA2‡, SMC1A‡ | 47,XY,+mar[2]/46,XY[18] | 7 + 3 and midostaurin | Induction | 4 | <5 | Yes | Yes |
| 3 | F | 66 | M5 | DNMT3A, IDH2, PTPN11, EZH2‡ | Normal | Decitabine and venetoclax | R/R | 24 | 8 | Yes | Yes |
| 4 | F | 60 | t-AML | IKZF1, BRAF‡, ETV6‡, RUNX1‡ | 47,XX,+8[20] | Liposomal daunorubicin-cytarabine | R/R | 10 | <5 | No | No |
| 5 | F | 65 | t-AML | NF1, TP3, CD79a‡ | Complex (monosomal) | Busulfan & cyclophosphamide | Conditioning for HSCT | 53 | 9 | Yes | Yes |
| 6 | M | 62 | t-AML | DNMT3A, JAK2, PLCG1‡ | 45,X,-Y,t(7;21;8)(q11.2;q22;q21.3)[19]/46,XY[1] | Azacitidine and venetoclax | R/R | 7 | 26 | Yes | No |
| Patient no. . | Sex . | Age, y . | AML genetics∗ . | Recent or current chemotherapy treatment . | Treatment line . | Platelet count . | Vc level (μmol/L) . | Malnutrition present (yes/no)† . | Parental nutrition . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Subtype . | Pathologic variants present . | Karyotype . | |||||||||
| 1 | F | 57 | AML-MRC | BRAF, NF1, NPM1, DNMT3A‡ | 46,XX,-18,+r[5]/46.XX[15] | Liposomal daunorubicin-cytarabine | Induction | 20 | 7 | Yes | No |
| 2 | M | 73 | M5 | DNMT3A, FLT3, NPM1, BRCA2‡, SMC1A‡ | 47,XY,+mar[2]/46,XY[18] | 7 + 3 and midostaurin | Induction | 4 | <5 | Yes | Yes |
| 3 | F | 66 | M5 | DNMT3A, IDH2, PTPN11, EZH2‡ | Normal | Decitabine and venetoclax | R/R | 24 | 8 | Yes | Yes |
| 4 | F | 60 | t-AML | IKZF1, BRAF‡, ETV6‡, RUNX1‡ | 47,XX,+8[20] | Liposomal daunorubicin-cytarabine | R/R | 10 | <5 | No | No |
| 5 | F | 65 | t-AML | NF1, TP3, CD79a‡ | Complex (monosomal) | Busulfan & cyclophosphamide | Conditioning for HSCT | 53 | 9 | Yes | Yes |
| 6 | M | 62 | t-AML | DNMT3A, JAK2, PLCG1‡ | 45,X,-Y,t(7;21;8)(q11.2;q22;q21.3)[19]/46,XY[1] | Azacitidine and venetoclax | R/R | 7 | 26 | Yes | No |
AML-MRC, AML with myelodysplasia-related changes; F, female; HSCT, hematopoietic stem cell transplantation (both allo/auto); IDG2, isocitrate dehydrogenase 2; M, male; R/R, relapsed/refractory; 7 + 3, cytarabine and daunorubicin; t-AML, treatment-related AML.
At the time of AML diagnosis.
Severe protein calorie malnutrition, as established by a registered dietician.
Variant of unknown significance; however, the allele frequency was >15%.